Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety

We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open‐label, parallel‐design study in participants with normal renal function (n = 6), severe renal impairment (RI; n =...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Edward, Gibbs, John P., Emery, Maurice G., Block, Geoffrey, Wasserman, Scott M., Hamilton, Lisa, Kasichayanula, Sreeneeranj, Hanafin, Patrick, Somaratne, Ransi, Egbuna, Ogo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590207/
https://www.ncbi.nlm.nih.gov/pubmed/30676701
http://dx.doi.org/10.1002/cpdd.650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590207/
https://www.ncbi.nlm.nih.gov/pubmed/30676701
http://dx.doi.org/10.1002/cpdd.650

Ejemplares similares